Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

The evidence includes treatment persistence in a U.S. claims cohort and prolonged transfusion independence in two Korean patients.

Rhea-AI Summary

Geron (GERN) announced presentations on imetelstat in lower-risk myelodysplastic syndromes at hematology congresses in Japan and German-speaking Europe.

The two oral presentations and one poster cover real-world evidence and IMerge clinical findings. In a U.S. claims cohort of 58 patients, 71% started imetelstat in the third treatment line or later; approximately 67% remained on therapy at six months, based on a statistical estimate. Two Korean patients achieved over one year without red blood cell transfusions. Both experienced early severe reductions in neutrophils and platelets; most events improved to grade 2 or lower in under four weeks. A separate presentation examines molecular findings and potential improvements in health-related outcomes.

Positive

• Minor pointApproximately 67% of the 58-patient U.S. cohort remained on treatment at six months, using a Kaplan-Meier estimate.
• Minor pointTwo Korean patients achieved over one year of red blood cell transfusion independence with imetelstat.
• Minor pointMost severe blood-cell reduction events in the two long-term Korean responders improved within less than four weeks.
• Minor pointEarly blood-cell reductions were associated with better clinical outcomes in 13 Korean IMerge patients.
• Minor point. Forward-looking: it has not happened yet and may not happen.Emerging molecular evidence suggests imetelstat may potentially alter the underlying disease biology.
• Minor pointSustained transfusion independence may accompany improved fatigue and quality-of-life measures in certain patients.

Negative

• Minor pointBoth long-term Korean responders experienced early grade 3/4 neutropenia and thrombocytopenia, severe reductions in neutrophils and platelets.
• Minor pointU.S. real-world evidence comes from a retrospective claims study involving 58 patients.
• Minor pointKorean findings come from a post-hoc analysis covering 13 patients, including the two long-term responders.

Key Figures

U.S. real-world cohort: 58 patients Third-line or later initiation: 71% Remained on therapy: ~67% at 6 months +3 more

U.S. real-world cohort

58 patients

Imetelstat-treated lower-risk MDS cohort

Third-line or later initiation

71%

U.S. real-world cohort

Remained on therapy

~67% at 6 months

U.S. real-world cohort; Kaplan-Meier estimate

Long-term red blood cell transfusion independence

Over 1 year

Two Korean patients with lower-risk MDS

Korean patient analysis

13 patients

Phase 2/3 and QTc substudy of IMerge

Early cytopenia events

Grade 3/4 neutropenia and thrombocytopenia in both patients

Long-term responders; most events resolved to grade ≤2 in <4 weeks

Key Terms

cytopenias, kaplan-meier, qtc, erythropoiesis-stimulating agents, +1 more

5 terms

cytopenias medical

"when cytopenias typically emerge"

Cytopenias are reductions in one or more types of blood cells — red cells, white cells or platelets — that can lead to anemia, infection risk or bleeding problems. For investors, cytopenias matter because they are common safety signals in clinical trials and marketed therapies; persistent or severe cytopenias can force dose changes, regulatory restrictions, or product withdrawals, affecting a drug’s commercial prospects and a company’s valuation.

kaplan-meier technical

"Kaplan-Meier [KM] estimate"

A Kaplan-Meier estimate is a statistical curve that shows how long it takes for a particular event—such as recovery, relapse, or death—to occur in a group over time, with the curve stepping down as events happen. Investors use these curves to assess the duration and timing of a treatment's or risk's effects—like watching how many light bulbs remain working week by week—because the timing and likelihood of outcomes influence clinical decisions, regulatory approval, and revenue prospects.

qtc medical

"heart rate-corrected QT interval (QTc) substudy"

QTc is the heart’s electrical “reset” time measured on an electrocardiogram and adjusted for heart rate; it shows how long the heart takes to recharge between beats. Investors care because an unusually long QTc can signal a risk of dangerous arrhythmias, which can prompt safety warnings, clinical hold decisions, or regulatory scrutiny for drugs and medical devices—events that can materially affect a company’s value and prospects.

erythropoiesis-stimulating agents medical

"ineligible for erythropoiesis-stimulating agents (ESAs)"

Drugs that stimulate the body to produce more red blood cells, used to treat anemia from chronic illness or medical treatments. They matter to investors because approvals, safety findings, patent status and reimbursement rules directly affect sales, company valuations and healthcare costs—think of them as a factory upgrade that increases the supply of oxygen-carrying cells, where regulators and payers control how fast and widely that upgrade can be used.

telomerase inhibitor medical

"RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor"

A telomerase inhibitor is a drug that blocks telomerase, an enzyme some cells use to keep protective caps on the ends of their chromosomes so they can keep dividing. Investors care because blocking this enzyme can slow or stop growth of certain cancers and affect drug development value, much like cutting off a plant’s water supply to stop it from spreading; success or failure in trials and regulatory approval can strongly affect a company’s future revenue and stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat 

FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced two oral presentations and one poster presentation highlighting imetelstat in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the 88^th Annual Meeting of the Japanese Society of Hematology and the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology. These presentations will feature real-world evidence and findings from the Phase 3 IMerge trial.

“We’re encouraged by the growing interest in imetelstat across the global hematology community, supported by both the clinical evidence from IMerge and an expanding body of real-world evidence in lower-risk MDS,” said Joseph E. Eid, M.D., Executive Vice President, Research and Development and Chief Medical Officer of Geron. “These presentations provide an important opportunity to share evidence relevant to patient populations across regions and engage with clinicians as we evaluate opportunities to bring imetelstat’s potential to more people living with LR-MDS around the world.”

Key takeaways from the presentations:

88^th Annual Meeting of the Japanese Society of Hematology 2026

• Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic Syndromes: Insights From United States Claims Data (Eid, et al. Oral #O1-11C-4)
  • The retrospective study used closed medical and pharmacy claims with linked enrollment and laboratory data from the Komodo Health database and included adults with MDS who initiated imetelstat between June 2024 and August 2025, representing the first 14 months after the launch of imetelstat in the U.S.
  • In this real-world U.S. cohort (N=58), with a mean age of 75 years at diagnosis, most patients (71%) initiated imetelstat in the third line or later, with considerable anemia and a mean Charleson Comorbidity Index of 2.6 at the time of initiation.
  • Despite substantial comorbidity burden, most patients remained on therapy through the early months when cytopenias typically emerge (~67% at 6 months; Kaplan-Meier [KM] estimate).

• Durable Clinical Outcomes With Imetelstat in Korean Patients With LR-MDS (Eid, et al. Poster #P3-12-5)
  • This post-hoc study explores characteristics of two Korean patients with LR-MDS who had over one year of red blood cell transfusion independence (RBC-TI) with imetelstat, and explores the relationship between cytopenias and treatment outcomes with imetelstat in 13 Korean patients from the Phase 2/3 and heart rate-corrected QT interval (QTc) substudy of IMerge.
  • Both patients who achieved long-term response with imetelstat experienced grade 3/4 neutropenia and grade 3/4 thrombocytopenia events early during treatment; most resolved to grade ≤2 in <4 weeks, consistent with the broader IMerge data.
  • Durable efficacy and manageable safety with imetelstat was exhibited in Korean patients across a range of patient and disease characteristics (sex, RS status, baseline erythropoietin [EPO], and baseline platelet levels).
  • In the 13 Korean patients, early cytopenias with imetelstat were associated with better clinical outcomes, as previously reported in IMerge.
    
    

2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology

• Telomerase Inhibition With Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes (Brauer, et al. Oral #V755)
  • This presentation integrates key evidence from the Phase 2/3 and QTc substudy of IMerge to support clinical practice, reporting on molecular changes, cytopenias and clinical outcomes with imetelstat in LR-MDS, including emerging evidence suggesting treatment may potentially alter the underlying biology of the disease.
  • Transient cytopenias observed early in treatment may be the result of an on-target effect of imetelstat and may be predictive of a better therapeutic response.
  • Certain patients with LR-MDS and transfusion-dependent (TD) anemia who experience sustained RBC-TI (≥8-week, ≥24-week, or ≥1-year) with imetelstat may experience improved health-related outcomes, including fatigue, QUALMS Total, QUALMS-P, and QUALMS-E scores.

The presentations are available on the “Publications & Presentations” page of the Geron website.

About RYTELO (imetelstat)
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO^® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Use of Forward-Looking Statements

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, those regarding: (i) the potential clinical significance of data presented from the IMerge trial and real-world evidence analyses; (ii) the potential relationship between treatment-emergent cytopenias and clinical outcomes; (iii) the potential for imetelstat to affect the underlying biology of lower-risk MDS; (iv) Geron’s plans and efforts to expand awareness and understanding of imetelstat through scientific engagement; (v) Geron’s plans to pursue opportunities to bring imetelstat to patients outside the United States; (vi) the future development of imetelstat in lower-risk myelodysplastic syndromes, myelofibrosis and other hematologic malignancies; and (vii) other statements that are not historical facts. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether data analyses and observations from clinical trials and real-world experience are predictive of future clinical outcomes; (b) whether imetelstat demonstrates disease-modifying activity or other benefits in patients; (c) whether treatment-emergent cytopenias are predictive of clinical outcomes or reflect on-target biological activity; (d) whether future clinical trial results, analyses and observations are consistent with prior findings; (e) whether regulatory authorities permit the continued development of imetelstat on a timely basis, or at all; (f) whether Geron is successful in commercializing RYTELO outside of the United States; (g) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO or clinical trial materials; and (h) risks and uncertainties relating to the development, regulatory review, and commercialization and market acceptance of imetelstat. Additional information regarding these risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Geron's imetelstat real-world study show about treatment persistence?

Approximately 67% of the 58 patients remained on imetelstat at six months, based on a Kaplan-Meier statistical estimate. Patients had a mean age of 75 years at diagnosis, and 71% started imetelstat in the third treatment line or later.

What data did Geron use for the U.S. imetelstat real-world study?

The retrospective study used Komodo Health closed medical and pharmacy claims linked to enrollment and laboratory data. It included adults with myelodysplastic syndromes who started imetelstat between June 2024 and August 2025, representing the first 14 months after its U.S. launch.